FindTrial
Sign In

A multigene assay to predict distant recurrence of early breast cancer lesion

A multigene assay to predict distant recurrence of early breast cancer lesion

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070625
Enrollment
Unknown
Registered
2023-04-18
Start date
2023-05-01
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Female patients with early breast cancer:None

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1) Women with clinically diagnosed early breast cancer; 2) HR+, HER2-; 3) sufficient and qualified tissue samples for genetic testing; 4) Able to comply with the study and follow-up procedures.

Exclusion criteria

Exclusion criteria: 1) clinically diagnosed advanced breast cancer or recurrent breast cancer; 2) HR-negative, HER2-positive or triple-negative breast cancer by immunohistochemistry; 3) complicated with other malignant tumors within 5 years; 4) Patients whose clinical diagnosis and treatment information is incomplete and cannot meet the requirements of data analysis; 5) The sample volume and quality did not support patients with genetic testing needs.

Design outcomes

Primary

MeasureTime frame
distant recurrence-free interval;—

Countries

China

Contacts

Public ContactTing Luo

West China Hospital, Sichuan University

luoting@wchscu.cn+86 18980606230

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026